What is the 13F Pro Quality Score for ONC?

13F Pro ranks BeOne Medicines Ltd. (ONC) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View ONC's current score at https://13fpro.ai/research/ONC (free sign-up required for the full ranking).

Where does 13F Pro source ONC data?

All BeOne Medicines Ltd. fundamentals and ownership data come directly from SEC EDGAR. BeOne Medicines Ltd. files with the SEC under CIK 1651308. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is ONC in?

BeOne Medicines Ltd. (ONC) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is ONC research updated on 13F Pro?

ONC's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

BeOne Medicines Ltd.(ONC)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1651308 ONC stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Pending next ranking run

This company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. Rankings refresh on Jan 1, Apr 1, Jul 1, Oct 1.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

ONC Stock Analysis & AI Quality Score

AI stock analysis and institutional research for BeOne Medicines Ltd. (ONC), a Healthcare sector company. ONC is not currently included in 13F Pro's AI-ranked quality universe — this company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. rankings refresh on jan 1, apr 1, jul 1, oct 1. Based on the latest XBRL financial filings (Q1 2026), BeOne Medicines Ltd. reports quarterly revenue of $1.5B, net income of $227.4M, free cash flow of $160.5M. Top institutional holders of ONC by reported 13-F value include BAKER BROS. ADVISORS, PRIMECAP MANAGEMENT CO/CA/, Capital International Investors, based on the most recent SEC filings. ONC trades on the Nasdaq exchange and files with the SEC under CIK 1651308. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ONC daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for BeOne Medicines Ltd. directly from SEC EDGAR.

Revenue

Q1 2026

$1.5B

Net Income

Q1 2026

$227.4M

Free Cash Flow

Q1 2026

$160.5M

ROIC

Q1 2026

4.5%

D/E Ratio

Q1 2026

0.23

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+223.9% YoY

$3.81BFY 2024

FY19 $428.2MFY20 $308.9MFY21 $1.18BFY24 $3.81B

Net Income

+55.8% YoY

$-644.8MFY 2024

FY19 $-948.6MFY20 $-1.62BFY21 $-1.46BFY24 $-644.8M

Operating Income

+60.5% YoY

$-568.2MFY 2024

FY19 $-959.9MFY20 $-1.66BFY21 $-1.44BFY24 $-568.2M

EPS (Diluted)

+61.2% YoY

$-0.47FY 2024

FY19 $-1.22FY20 $-1.50FY21 $-1.21FY24 $-0.47

Total Assets

-30.6% YoY

$5.92BFY 2024

FY19 $1.61BFY20 $5.60BFY21 $8.54BFY24 $5.92B

Total Debt

+9.0% YoY

$1.87BFY 2024

FY19 $83.3MFY20 $3.72BFY21 $1.72BFY24 $1.87B

Op. Cash Flow

+89.2% YoY

$-140.6MFY 2024

FY19 $-750.3MFY20 $-1.28BFY21 $-1.30BFY24 $-140.6M

Metric	FY 2024	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017
Revenue	$3.81B +223.9%	$1.18B +280.8%	$308.9M -27.9%	$428.2M +116.0%	$198.2M -16.8%	$238.4M
Net Income	$-644.8M +55.8%	$-1.46B +10.3%	$-1.62B -71.3%	$-948.6M -40.8%	$-673.8M -623.7%	$-93.1M
Operating Income	$-568.2M +60.5%	$-1.44B +13.2%	$-1.66B -72.7%	$-959.9M -36.0%	$-705.8M -616.8%	$-98.5M
EPS (Diluted)	$-0.47 +61.2%	$-1.21 +19.3%	$-1.50 -23.0%	$-1.22	—	—
Total Assets	$5.92B -30.6%	$8.54B +52.4%	$5.60B +247.4%	$1.61B -28.3%	$2.25B +115.0%	$1.05B
Total Debt	$1.87B +9.0%	$1.72B -53.9%	$3.72B +4364.2%	$83.3M +68.3%	$49.5M +168.4%	$18.4M
Operating Cash Flow	$-140.6M +89.2%	$-1.30B -1.2%	$-1.28B -71.1%	$-750.3M -37.0%	$-547.7M -4395.1%	$12.8M

AI Insight: ONC Financial Trends

BeOne inflected to sustained profitability in 2025, with operating income surging from -$120M in Q3 2024 to $250M in Q1 2026 on 51% revenue growth.

• Revenue grew 51% from $1,002M in Q3 2024 to $1,513M in Q1 2026, with eight consecutive quarters of sequential gains.

• Operating income swung from -$120M in Q3 2024 to $250M in Q1 2026, marking a clear and accelerating profitability inflection.

• Operating cash flow turned consistently positive, rising from -$96M in Q2 2024 to $417M in Q4 2025, though it dipped to $201M in Q1 2026.

• Equity expanded from $3,332M in Q4 2024 to $4,760M in Q1 2026, strengthening the balance sheet alongside rising profitability.

⚠ Total debt spiked to $7,431M in Q4 2024 before collapsing to $813M–$1,088M — the spike's nature warrants clarification.

⚠ Net income of $67M in Q4 2025 lagged operating income of $185M, suggesting below-the-line charges worth monitoring.

⚠ Operating cash flow fell to $201M in Q1 2026 from $417M in Q4 2025 — early sign of working-capital pressure or seasonal effect.

AI Insight: ONC Ratio Trends

BeOne Medicines flipped from deeply negative margins to a 16.5% operating margin in Q1 2026, marking a dramatic profitability inflection within four quarters.

• Operating margin surged from -12.0% in Q3 2024 to 16.5% in Q1 2026 — a nearly 29 percentage-point swing in five quarters.

• ROIC turned positive in Q1 2025 at 1.0% and accelerated to 17.1% by Q1 2026, signaling increasingly productive capital deployment.

• Leverage normalized sharply: D/E collapsed from 2.23 in Q4 2024 to 0.23 in Q1 2026, strengthening the balance sheet materially.

• Net profit margin dipped to 4.4% in Q4 2025 versus 8.8% in Q3 2025, before rebounding to 15.0% in Q1 2026 — suggesting Q4 seasonality or one-off items.

⚠ Q4 2025 NPM fell sharply to 4.4% while operating margin held at 12.3% — the below-the-line gap warrants monitoring for recurring non-operating costs.

⚠ TTM ROIC of 11.7% lags the Q1 2026 quarterly read of 17.1%; sustaining the recent improvement across full-year results is unconfirmed.

Get alerted when ONC's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for BeOne Medicines Ltd. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of ONC

BAKER BROS. ADVISORS LP
$2.6B8,799,053 sh
PRIMECAP MANAGEMENT CO/CA/
$1.5B4,975,181 sh
Capital International Investors
$1.2B4,158,726 sh
FMR LLC
$1.1B3,693,610 sh
Capital World Investors
$481.9M1,622,687 sh
Hillhouse Capital Advisors, Ltd.
$307.2M1,034,306 sh
CITADEL ADVISORS LLC
$306.6M1,032,298 sh
Temasek Holdings (Private) Ltd
$256.2M862,643 sh
BlackRock, Inc.
$195.3M657,501 sh
Siren, L.L.C.
$138.1M465,000 sh

Fund	Value	Shares
BAKER BROS. ADVISORS LP	$2.6B	8,799,053
PRIMECAP MANAGEMENT CO/CA/	$1.5B	4,975,181
Capital International Investors	$1.2B	4,158,726
FMR LLC	$1.1B	3,693,610
Capital World Investors	$481.9M	1,622,687
Hillhouse Capital Advisors, Ltd.	$307.2M	1,034,306
CITADEL ADVISORS LLC	$306.6M	1,032,298
Temasek Holdings (Private) Ltd	$256.2M	862,643
BlackRock, Inc.	$195.3M	657,501
Siren, L.L.C.	$138.1M	465,000

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put ONC on your watchlist

Track score changes the day BeOne Medicines Ltd. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is ONC a good stock to buy?

13F Pro's AI-powered analysis of BeOne Medicines Ltd. (ONC) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for ONC are available on the ONC stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own ONC?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling ONC. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of BeOne Medicines Ltd.'s investment landscape.